Navigation Links
Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles

SAN FRANCISCO, Nov. 7 /PRNewswire/ -- Epiphany Biosciences announced today that the first patient was enrolled in a Phase 2b clinical trial with valomaciclovir (EPB-348) for the treatment of herpes zoster, also known as shingles. Valomaciclovir is a highly potent anti-viral with enhanced delivery and bioavailability.

"The initiation of this dose-finding study is an important milestone in our development of valomaciclovir," said Fred Volinsky, MD, Chief Executive Officer. "Shingles, especially in the elderly population, can pose a serious threat to quality of life. Despite the approval of the adult zoster vaccine, we believe that the potential market for effective zoster medications will double in size based on the published vaccine efficacy rates and the aging of the baby boomers."

"There are roughly one million cases of herpes zoster in the United States annually and current therapy requires multiple dosing, anywhere from three to five times a day. These dosing schedules can be problematic for patient populations who are already taking multiple medications for other co-morbid conditions," stated Brian Murphy, MD, Chief Medical Officer. "This clinical trial is designed to examine the safety and efficacy of once-daily valomaciclovir against an active comparator, three times daily valacyclovir, and is adequately powered to assess a number of pivotal outcomes."

"Advancing a therapy that is conducive to better compliance is sorely needed in this therapeutic space," noted Dr. Stephen Tyring, Professor of Medicine at the University of Texas Health Science Center in Houston and principal investigator for the study. "In light of the improved pharmacodynamic profile offered by this drug, it is important to study it in larger, diverse populations that can be affected by herpes zoster."

The number of elderly patients at-risk for this disease is expected to increase dramatically over the next decade as the world population ages. "While we are working to advance valomaciclovir to become the next global brand for the management of shingles, we are pleased that this compound also exhibits activity both in vitro and in vivo against other types of viruses. We plan to explore these potential broad therapeutic possibilities given the spectrum of this anti-viral profile," said Dr. Volinsky.

About Epiphany Biosciences

Epiphany Biosciences is focused on advancing new therapies for viral disease. Epiphany has formed a world-class virology team that includes two Lasker Award winners. Epiphany is located in San Francisco, CA. Additional information on Epiphany Biosciences may be obtained at the company website,, or by contacting company representatives at 415.765.7193.

SOURCE Epiphany Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
(Date:11/26/2015)... -- Research and Markets ( ) has announced ... by Type (Dressings, Therapy Devices, Active Wound Care), Application ... and Geography - Global Forecast to 2020" report ... --> The purpose of this report is ... global advanced wound care market. It involves deep dive ...
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Italian ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
Breaking Medicine Technology:
(Date:11/29/2015)... Aliso Viejo, CA (PRWEB) , ... November 29, ... ... is an all new and unique analog distortion effect tool designed specially for ... to their footage, and create limiltess looks with the easy-to-use modification controls. Destoying ...
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices ... inventors, one from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, ... to save the expense of having to replace NuvaRings more often than necessary. As ...
(Date:11/27/2015)... , ... November 28, 2015 , ... There is only ... outperform our billings from last year? , This question has not been an easy ... coming to the retirement age and the younger workforce don’t share the same discipline ...
(Date:11/27/2015)... ... , ... The rapid speed at which Americans are aging ... is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming more prevalent. ... part of this equation: 80 percent of medical care occurs in the home, ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... Lizzie’s ... , The company is offering customers 10% off of their purchase of lice treatment ... treatment at full price. According to a company spokesperson. “Finding lice is a sure ...
Breaking Medicine News(10 mins):